罗沙司他治疗慢性肾脏病维持性血液透析患者的临床效果及对铁代谢、炎症因子的影响  

Clinical effect of Losartan on maintenance hemodialysis and its effect on iron metabolism and inflammatory factors

作　　者：张文彬 池向耿[1] 陈艳转 禤杏华[1] 蔡琪[1] ZHANG Wen-bin;CHI Xiang-geng;CHEN Yan-zhuan;XUAN Xing-hua;CAI Qi(Department of Renal Rheumatism Immunity,Xiaolan People′s Hospital,Guangdong Province,Zhongshan 528415,China)

机构地区：[1]广东省中山市小榄人民医院肾风湿免疫科,广东中山528415

出　　处：《中国当代医药》2021年第27期69-72,共4页China Modern Medicine

基　　金：广东省中山市卫生健康局医学科研项目(2020J 267)。

摘　　要：目的探究使用罗沙司他治疗慢性肾脏病(CKD)维持性血液透析(MHD)患者的临床疗效及对患者铁代谢和炎症因子的影响。方法选取2019年6月至2020年6月中山市小榄人民医院收治的50例接受维持性血液透析的CKD患者作为研究对象,按照随机数字表法分为治疗组和对照组,每组各25例。治疗组采用罗沙司他进行治疗,对照组接受常规传统肾性贫血治疗,比较两组患者临床疗效差异及患者C反应蛋白(CRP)、白介素6(IL-6)、铁蛋白(SF)、转铁蛋白饱和度(TSAT)的变化情况。结果治疗3个月后,治疗组患者的临床治疗总有效率高于对照组,差异有统计学意义(P<0.05)。两组患者治疗前以及治疗1个月后时的CRP、IL-6、TSAT、SF指标比较,差异无统计学意义(P>0.05)。治疗2、3个月后,治疗组的CRP、IL-6、SF低于对照组,TSAT高于对照组,差异有统计学意义(P<0.05)。两组的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论罗沙司他治疗维持性血液透析CKD患者能够有效改善患者贫血症状,缓解微炎症状态还具有较高的安全性。Objective To explore the clinical efficacy of Losartan in the treatment of maintenance hemodialysis(MHD)patients with chronic kidney disease(CKD)and its effect on iron metabolism and inflammatory factors.Methods A total of 50 patients with CKD who received maintenance hemodialysis in Xiaolan people′s Hospital of Zhongshan City from June 2019 to June 2020 were selected as the research objects.They were randomly divided into the treatment group and the control group,with 25 cases in each group.The treatment group was treated with Losartan,while the control group was treated with conventional renal anemia The changes of C-reactive protein(CRP),interleukin-6(IL-6),ferritin(SF)and transferin saturation(TSAT)were observed.Results After 3 months of treatment,the total clinical effective rate of the treatment group was higher than that of the control group,and the difference was statistically significant(P<0.05).There were no significant differences in CRP,IL-6,TSAT and SF between the two groups before treatment and one month after treatment(P>0.05).After 2 and 3 months of treatment,CRP,IL-6 and SF in the treatment group were lower than those in the control group,and TSAT was higher than that in the control group,with statistical significances(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Losartan in the treatment of maintenance hemodialysis patients with CKD can effectively improve the symptoms of anemia,relieve the micro inflammatory state,and has high safety.

关 键 词：罗沙司他 维持性血液透析 贫血 C-反应蛋白 白介素-6 铁蛋白 转铁蛋白饱和度 

分 类 号：R459.5[医药卫生—治疗学]